Journals / İstanbul Medical Journal / 2013 / Cilt: 14 - Sayı: 3

The Association of Uric Acid and Systolic Dysfunction in Patients with Cardiorenal Syndrome

Kardiyorenal Sendromu Olan Hastalarda Serum Ürik Asid Düzeyi ile Sistolik Disfonksiyon Arasındaki İlişki

Pages
184–187
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results consistently demonstrated that elevated uric acid levels were independently associated with the degree of left ventricular systolic dysfunction.Hyperuricemia is also a marker of impaired oxidative metabolism, which correlates with left ventricular systolic dysfunction in patients with the cardiorenal syndrome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Studies have shown that increased levels of serum uric acid (SUA) are associated with cardiovascular diseases.
📊
Key Findings & Data:Methods: We retrospectively assessed clinical characteristics, echocardiological and biochemical variables in patients with cardiorenal syndrome. 180 patients admitted to the Istanbul Education and Research Hospital were included into the study.
💡
Conclusion & Impact:Our results consistently demonstrated that elevated uric acid levels were independently associated with the degree of left ventricular systolic dysfunction.Hyperuricemia is also a marker of impaired oxidative metabolism, which correlates with left ventricular systolic dysfunction in patients with the cardiorenal syndrome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Studies have shown that increased levels of serum uric acid (SUA) are associated with cardiovascular diseases. In this study we investigated the effect of EF(ejection fraction) levels on serum uric acid levels in patients with cardiorenal syndrome. Methods: We retrospectively assessed clinical characteristics, echocardiological and biochemical variables in patients with cardiorenal syndrome. 180 patients admitted to the Istanbul Education and Research Hospital were included into the study. Patients were divided into 2 groups according to EF measurements; 30-45%, < 30% respectively. Results: As systolic dysfunction progresses, levels of serum uric acid also elevates. In our study there was a significiant difference between EF measurement and serum uric acid in two groups with the cardiorenal syndrome (p < 0.01). Conclusion: Elevated uric acid (UA) levels have been associated with cardiovascular disease in studies. Our results consistently demonstrated that elevated uric acid levels were independently associated with the degree of left ventricular systolic dysfunction.Hyperuricemia is also a marker of impaired oxidative metabolism, which correlates with left ventricular systolic dysfunction in patients with the cardiorenal syndrome.

Özet

Amaç: Çalışmalarda kardiyovasküler hastalık ile artmış ürik asit arasında ilişki gösterilmiştir. Biz bu çalışmada kardiyorenal sendromu olan hastalarda serum ürik asid düzeyi ile ejeksiyon fraksiyonu (EF) arasındaki ilişkiyi araştırdık. Yöntemler: Kardiyorenal sendromu olan hastalarda retrospektif olarak klinik bulguları, ekokardiyografik ve biyomkimyasal parametleri değerlendirdik. İstanbul Eğitim Araştırma Hastanesine başvurmuş 180 hasta çalış- maya alındı. Hastaları EF ölçümüne göre; EF < %30 olanlar ve EF %30-45 arasında olanlar olarak ikiye ayırdık. Bulgular: Sistolik disfonksiyon ilerledikçe serum ürik asid seviyesi de iliş- kili olarak artmaktadır. Bizim çalışmamızda kardiyorenal sendromu olan hastalarda iki grup arasında serum ürik asid düzeyi ve EF değerleri arasında anlamlı fark saptandı (p < 0,01). Sonuç: Birçok çalışmada artmış ürik asit seviyesi kardiyovasküler hastalıklar ile ilişkili bulunmuştur. Bizim çalışmamızda artmış ürik asit seviyelerinin sol ventrikül sistolik disfonksiyon derecesi ile ilişkili olduğu saptanmıştır. Hiperürisemi kardiorenal sendromu olanlarda sol ventriküler disfonksiyonu ile ilişkili bir artmış oksidatif metabolizma belirteci olabilir

🔖

Cite This Article

PİŞKİNPAŞA, M. E., CERİT, A., ZIRTILOĞLU, A., KARAGÖZ, H. (2022). The Association of Uric Acid and Systolic Dysfunction in Patients with Cardiorenal Syndrome. İstanbul Medical Journal, Cilt: 14 - Sayı: 3, 184–187. https://ajindex.com/articles/552242

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. American J Hypertensi?on 2005
  2. [CrossRef] 2. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, et al. Contras?tingroles of NADPH oxidaseisoforms in pressure-overload versus angioten?sin II-induced cardiac hypertrophy. Circ Res 2003
  3. [CrossRef] 3. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldostero?ne mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006
  4. [CrossRef] 4. Prasad K, Kalra J, Chan WP, Chaudhary AK. Effect of oxygen free radi?cals on cardiovascular function at organ and cellular levels. Am Heart J 1989
  5. [CrossRef] 5. Hess ML, Okabe E, Kontos HA. Proton and free oxygen radical interac?tion with the calcium transport system of cardiac sarcoplasmicreticu?lum. J Mol Cell Cardiol 1981
  6. [CrossRef] 6. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue in?jury. Lab Invest 1982
  7. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiurico?suric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997
  8. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, et al. Urica?cid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross over preliminary study. Circ Heart Fail 2010
  9. [CrossRef] 9. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopuri?nol improves endothelial function by profoundly reducing vascular oxidative stres and not by lowering uricacid. Circulation 2006
  10. [CrossRef] 10. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Rea?veley DA, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002
  11. [CrossRef] 11. Waring WS, McKnight JA, Webb DJ, Maxwell SR. Lowering serum urate does not improve endothelial function in patients with type 2 diabe?tes. Diabetologia 2007
  12. [CrossRef] 12. Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J 1999
  13. [CrossRef] 13. Mitsuhashi H, Yatsuya H, Matsushita K, Zhang H, Otsuka R, Muramat?su T, et al. Uric acid a